Vivus Inc (VVUS) 1.05 $VVUS
VIVUS Files Lawsuit Against Hetero for Infringement of Stendra Patents
Marketwired - Wed Jul 27, 3:16PM CDT
MOUNTAIN VIEW, CA--(Marketwired - July 27, 2016) - VIVUS, Inc. (NASDAQ: VVUS) today announced that it has filed a lawsuit in the U.S. District Court for the District of New Jersey against Hetero USA, Inc. and Hetero Labs Limited, collectively referred to as Hetero.
VVUS: 1.05 (-0.02)
VIVUS Announces Date of 2016 Second Quarter Business Update and Financial Results Teleconference
Marketwire Canada - Tue Jul 26, 3:15PM CDT
MOUNTAIN VIEW, CA--(Marketwired - July 26, 2016) - VIVUS, Inc. (NASDAQ: VVUS) today announced that it will report financial results and provide a business update for the second quarter of 2016 after the NASDAQ Market closes on Thursday, August 4, 2016. The company will conduct a conference call and an audio webcast at 4:30 pm EST the same day.
VVUS: 1.05 (-0.02)
Biotechnology Stocks Under the Scanner -- PTC Therapeutics, Inovio Pharma, VIVUS, and Spectrum Pharma
PR Newswire - Mon Jul 11, 7:23AM CDT
On Friday, July 08, 2016, the NASDAQ Composite ended the trading session at 4,956.76, up 1.64%; the Dow Jones Industrial Average advanced 1.40%, to finish at 18,146.74; and the S&P 500 closed at 2,129.90, up 1.53%. The gains were broad based as all the sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: PTC Therapeutics Inc. (NASDAQ: PTCT), Inovio Pharmaceuticals Inc. (NASDAQ: INO), VIVUS Inc. (NASDAQ: VVUS), and Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI). Learn more about these stocks by accessing their free notes at:
INO: 10.42 (+0.54), VVUS: 1.05 (-0.02), PTCT: 6.10 (+0.13), SPPI: 7.05 (+0.18)
Biotechnology Equities Technical Briefing -- PTC Therapeutics, Biogen, Progenics Pharma, and VIVUS
PR Newswire - Tue Jun 14, 6:35AM CDT
On Monday, June 13, 2016, the NASDAQ Composite ended the trading session at 4,848.44, down 0.94%; the Dow Jones Industrial Average edged 0.74% lower, to finish at 17,732.48; and the S&P 500 closed at 2,079.06, down 0.81%. Stock-Callers.com has initiated coverage on the following equities: PTC Therapeutics Inc. (NASDAQ: PTCT), Biogen Inc. (NASDAQ: BIIB), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), and VIVUS Inc. (NASDAQ: VVUS). Learn more about these stocks by accessing their free trade alerts at:
PGNX: 5.84 (-0.01), BIIB: 301.83 (+11.90), VVUS: 1.05 (-0.02), PTCT: 6.10 (+0.13)
Orexigen Stock Gains More than 50% on Markman Hearing
Arpita Dutt - Zacks Investment Research - Thu Jun 09, 7:58AM CDT
Orexigen's (OREX) shares shot up on a favorable Markman hearing in the Contrave patent infringement lawsuit.
OREX: 3.38 (+0.03), RTRX: 18.17 (+0.24), VVUS: 1.05 (-0.02), ARNA: 1.68 (+0.01)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of VIVUS Inc. - VVUS
PR Newswire - Tue May 17, 10:31AM CDT
Levi & Korsinsky announces it has commenced an investigation of VIVUS Inc. (NASDAQ: VVUS) concerning possible breaches of fiduciary duty by the board of directors of the company. To obtain additional information, go to:
VVUS: 1.05 (-0.02)
Shareholder Alert: Purcell Julie & Lefkowitz LLP Is Investigating VIVUS, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
PR Newswire - Mon May 16, 11:53AM CDT
Purcell Julie & Lefkowitz LLP, a securities class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of VIVUS, Inc. (NASDAQ: VVUS). On April 22, 2016, VIVUS's stock price closed at $1.80 per share. On May 3, 2016, VIVUS announced that its revenue for the first quarter of 2016 was $15.3 million, far less than the $32.2 million in revenue for the first quarter of 2015. VIVUS's stock price closed at $1.16 per share on May 13, 2016.
VVUS: 1.05 (-0.02)
Drug Stocks Reporting Early Next Week: TEVA, ARNA & More
Arpita Dutt - Zacks Investment Research - Fri May 06, 8:43AM CDT
Drug companies like Teva (TEVA) and Arena (ARNA) will be reporting results early next week.
BDSI: 2.41 (-0.14), INO: 10.42 (+0.54), VVUS: 1.05 (-0.02), TEVA: 53.61 (+0.11), ARNA: 1.68 (+0.01), PBYI: 49.04 (-0.85)
Arena (ARNA) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Wed May 04, 7:07AM CDT
Will Arena (ARNA) continue with its earnings streak in Q1?
OVAS: 5.24 (+0.20), JAZZ: 150.53 (-0.44), VVUS: 1.05 (-0.02), ARNA: 1.68 (+0.01)
Vivus reports 1Q loss
Automated Insights - Tue May 03, 3:37PM CDT
MOUNTAIN VIEW, Calif. (AP) _ Vivus Inc. (VVUS) on Tuesday reported a loss of $12.7 million in its first quarter.
VVUS: 1.05 (-0.02)
Vivus Reports 2016 First Quarter Financial Results
Marketwired - Tue May 03, 3:05PM CDT
VIVUS, Inc. (NASDAQ: VVUS) (the "Company"
, a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health, today provided a business update and reported its financial results for the first quarter ended March 31, 2016. The net loss for the 2016 first quarter was $12.7 million as compared to $15.5 million in 2015. Cash, cash equivalents and available-for-sale securities was $227.8 million at March 31, 2016.
VVUS: 1.05 (-0.02)
VIVUS Announces Date of 2016 First Quarter Business Update and Financial Results Teleconference
Marketwired - Tue Apr 19, 5:01PM CDT
VIVUS, Inc. (NASDAQ: VVUS) today announced that it will report financial results and provide a business update for the first quarter of 2016 after the NASDAQ Market closes on Tuesday, May 3, 2016. The company will conduct a conference call and an audio webcast at 4:30 pm EST the same day.
VVUS: 1.05 (-0.02)
Biotech Volatility Both Good And Bad
ACCESSWIRE - Thu Apr 07, 8:31AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 7, 2016 / Jim Cramer made a great point about investing in biotech's that I think is worth addressing. After the decline in the biotech industry last week, he announced he was a buyer. But, that's not the major point. He continued, expressing that there is huge risk involved in any biotech, but with that risk comes the opportunity for tremendous rewards.
CERU: 2.89 (unch), VVUS: 1.05 (-0.02), PETX: 7.50 (-0.09), GALE: 0.45 (+0.01)
VIVUS (VVUS) in Focus: Stock Jumps 6.4% in Session
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 7:05AM CDT
VIVUS Inc. (VVUS) was a big mover last session, as the company saw its shares rise more than 6% on the day.
VVUS: 1.05 (-0.02)
Stocks to Trade: Those Looking Can Consider This List
ACCESSWIRE - Thu Mar 31, 10:59AM CDT
MIAMI, FL / ACCESSWIRE / March 31, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. VVUS, COOL, SKYS, and GNCA have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
COOL: 4.03 (+3.32), SKYS: 2.54 (-0.01), VVUS: 1.05 (-0.02), GNCA: 4.00 (-0.07)
Support.com Appoints Lowell Robinson and Elizabeth Fetter to Board of Directors
BusinessWire - Tue Mar 15, 7:00AM CDT
Support.com, Inc. (NASDAQ:SPRT), makers of award-winning, cloud-based Nexus(R) software for Support Interaction Optimization (SIO) and a leading provider of tech support and turnkey support center services, today announced the appointment of Lowell Robinson and Elizabeth Fetter, both highly regarded and accomplished business executives with substantial public company board experience, to its Board as new independent directors, effective immediately.
YHOO: 38.80 (+0.61), IKAN: 2.74 (unch), ONE: 5.15 (+0.02), QTM: 0.64 (+0.03), MGRC: 31.56 (-0.31), SPRT: 0.87 (+0.01), C: 43.42 (-0.39), VVUS: 1.05 (-0.02), EVLV: 1.92 (+0.03)
VIVUS Files Lawsuit Against Hetero for Infringement of Stendra Patents
Marketwired - Wed Jul 27, 3:16PM CDT
MOUNTAIN VIEW, CA--(Marketwired - July 27, 2016) - VIVUS, Inc. (NASDAQ: VVUS) today announced that it has filed a lawsuit in the U.S. District Court for the District of New Jersey against Hetero USA, Inc. and Hetero Labs Limited, collectively referred to as Hetero.
VVUS: 1.05 (-0.02)
VIVUS Announces Date of 2016 Second Quarter Business Update and Financial Results Teleconference
Marketwire Canada - Tue Jul 26, 3:15PM CDT
MOUNTAIN VIEW, CA--(Marketwired - July 26, 2016) - VIVUS, Inc. (NASDAQ: VVUS) today announced that it will report financial results and provide a business update for the second quarter of 2016 after the NASDAQ Market closes on Thursday, August 4, 2016. The company will conduct a conference call and an audio webcast at 4:30 pm EST the same day.
VVUS: 1.05 (-0.02)
Biotechnology Stocks Under the Scanner -- PTC Therapeutics, Inovio Pharma, VIVUS, and Spectrum Pharma
PR Newswire - Mon Jul 11, 7:23AM CDT
On Friday, July 08, 2016, the NASDAQ Composite ended the trading session at 4,956.76, up 1.64%; the Dow Jones Industrial Average advanced 1.40%, to finish at 18,146.74; and the S&P 500 closed at 2,129.90, up 1.53%. The gains were broad based as all the sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: PTC Therapeutics Inc. (NASDAQ: PTCT), Inovio Pharmaceuticals Inc. (NASDAQ: INO), VIVUS Inc. (NASDAQ: VVUS), and Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI). Learn more about these stocks by accessing their free notes at:
INO: 10.42 (+0.54), VVUS: 1.05 (-0.02), PTCT: 6.10 (+0.13), SPPI: 7.05 (+0.18)
Biotechnology Equities Technical Briefing -- PTC Therapeutics, Biogen, Progenics Pharma, and VIVUS
PR Newswire - Tue Jun 14, 6:35AM CDT
On Monday, June 13, 2016, the NASDAQ Composite ended the trading session at 4,848.44, down 0.94%; the Dow Jones Industrial Average edged 0.74% lower, to finish at 17,732.48; and the S&P 500 closed at 2,079.06, down 0.81%. Stock-Callers.com has initiated coverage on the following equities: PTC Therapeutics Inc. (NASDAQ: PTCT), Biogen Inc. (NASDAQ: BIIB), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), and VIVUS Inc. (NASDAQ: VVUS). Learn more about these stocks by accessing their free trade alerts at:
PGNX: 5.84 (-0.01), BIIB: 301.83 (+11.90), VVUS: 1.05 (-0.02), PTCT: 6.10 (+0.13)
Orexigen Stock Gains More than 50% on Markman Hearing
Arpita Dutt - Zacks Investment Research - Thu Jun 09, 7:58AM CDT
Orexigen's (OREX) shares shot up on a favorable Markman hearing in the Contrave patent infringement lawsuit.
OREX: 3.38 (+0.03), RTRX: 18.17 (+0.24), VVUS: 1.05 (-0.02), ARNA: 1.68 (+0.01)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of VIVUS Inc. - VVUS
PR Newswire - Tue May 17, 10:31AM CDT
Levi & Korsinsky announces it has commenced an investigation of VIVUS Inc. (NASDAQ: VVUS) concerning possible breaches of fiduciary duty by the board of directors of the company. To obtain additional information, go to:
VVUS: 1.05 (-0.02)
Shareholder Alert: Purcell Julie & Lefkowitz LLP Is Investigating VIVUS, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
PR Newswire - Mon May 16, 11:53AM CDT
Purcell Julie & Lefkowitz LLP, a securities class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of VIVUS, Inc. (NASDAQ: VVUS). On April 22, 2016, VIVUS's stock price closed at $1.80 per share. On May 3, 2016, VIVUS announced that its revenue for the first quarter of 2016 was $15.3 million, far less than the $32.2 million in revenue for the first quarter of 2015. VIVUS's stock price closed at $1.16 per share on May 13, 2016.
VVUS: 1.05 (-0.02)
Drug Stocks Reporting Early Next Week: TEVA, ARNA & More
Arpita Dutt - Zacks Investment Research - Fri May 06, 8:43AM CDT
Drug companies like Teva (TEVA) and Arena (ARNA) will be reporting results early next week.
BDSI: 2.41 (-0.14), INO: 10.42 (+0.54), VVUS: 1.05 (-0.02), TEVA: 53.61 (+0.11), ARNA: 1.68 (+0.01), PBYI: 49.04 (-0.85)
Arena (ARNA) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Wed May 04, 7:07AM CDT
Will Arena (ARNA) continue with its earnings streak in Q1?
OVAS: 5.24 (+0.20), JAZZ: 150.53 (-0.44), VVUS: 1.05 (-0.02), ARNA: 1.68 (+0.01)
Vivus reports 1Q loss
Automated Insights - Tue May 03, 3:37PM CDT
MOUNTAIN VIEW, Calif. (AP) _ Vivus Inc. (VVUS) on Tuesday reported a loss of $12.7 million in its first quarter.
VVUS: 1.05 (-0.02)
Vivus Reports 2016 First Quarter Financial Results
Marketwired - Tue May 03, 3:05PM CDT
VIVUS, Inc. (NASDAQ: VVUS) (the "Company"
, a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health, today provided a business update and reported its financial results for the first quarter ended March 31, 2016. The net loss for the 2016 first quarter was $12.7 million as compared to $15.5 million in 2015. Cash, cash equivalents and available-for-sale securities was $227.8 million at March 31, 2016. VVUS: 1.05 (-0.02)
VIVUS Announces Date of 2016 First Quarter Business Update and Financial Results Teleconference
Marketwired - Tue Apr 19, 5:01PM CDT
VIVUS, Inc. (NASDAQ: VVUS) today announced that it will report financial results and provide a business update for the first quarter of 2016 after the NASDAQ Market closes on Tuesday, May 3, 2016. The company will conduct a conference call and an audio webcast at 4:30 pm EST the same day.
VVUS: 1.05 (-0.02)
Biotech Volatility Both Good And Bad
ACCESSWIRE - Thu Apr 07, 8:31AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 7, 2016 / Jim Cramer made a great point about investing in biotech's that I think is worth addressing. After the decline in the biotech industry last week, he announced he was a buyer. But, that's not the major point. He continued, expressing that there is huge risk involved in any biotech, but with that risk comes the opportunity for tremendous rewards.
CERU: 2.89 (unch), VVUS: 1.05 (-0.02), PETX: 7.50 (-0.09), GALE: 0.45 (+0.01)
VIVUS (VVUS) in Focus: Stock Jumps 6.4% in Session
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 7:05AM CDT
VIVUS Inc. (VVUS) was a big mover last session, as the company saw its shares rise more than 6% on the day.
VVUS: 1.05 (-0.02)
Stocks to Trade: Those Looking Can Consider This List
ACCESSWIRE - Thu Mar 31, 10:59AM CDT
MIAMI, FL / ACCESSWIRE / March 31, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. VVUS, COOL, SKYS, and GNCA have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
COOL: 4.03 (+3.32), SKYS: 2.54 (-0.01), VVUS: 1.05 (-0.02), GNCA: 4.00 (-0.07)
Support.com Appoints Lowell Robinson and Elizabeth Fetter to Board of Directors
BusinessWire - Tue Mar 15, 7:00AM CDT
Support.com, Inc. (NASDAQ:SPRT), makers of award-winning, cloud-based Nexus(R) software for Support Interaction Optimization (SIO) and a leading provider of tech support and turnkey support center services, today announced the appointment of Lowell Robinson and Elizabeth Fetter, both highly regarded and accomplished business executives with substantial public company board experience, to its Board as new independent directors, effective immediately.
YHOO: 38.80 (+0.61), IKAN: 2.74 (unch), ONE: 5.15 (+0.02), QTM: 0.64 (+0.03), MGRC: 31.56 (-0.31), SPRT: 0.87 (+0.01), C: 43.42 (-0.39), VVUS: 1.05 (-0.02), EVLV: 1.92 (+0.03)
